MedTrace Logo

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

NCT06716645 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2026-02-20

Study results available
· View outcomes & findings →

Summary

The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.

Conditions

Interventions

DRUG

Robitussin Maximum Strength Cough and Chest Congestion DM

Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg

DRUG

Robitussin Maximum Strength Cough and Chest Congestion DM

Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg

DRUG

Robitussin Maximum Strength Nighttime Cough DM

Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg

Sponsors & Collaborators

  • HALEON

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2025-02-14
Completion
2025-02-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06716645 on ClinicalTrials.gov